Biomarker-Driven Therapy Launch Strategies for Global Success

Launching a predictive biomarker-driven therapy is inherently complex, particularly when it is tied to companion diagnostics or lab-developed tests.

Teams often struggle to align scientific validation, market access and diagnostic readiness across global settings.

Join this webinar, tailored for pharmaceutical professionals in Medical Affairs, Diagnostics, Precision Medicine and Commercialization, to explore actionable solutions that streamline rollout and improve patient access.

The featured speakers will explore the multidisciplinary steps required for a successful launch, focusing on the pivotal role of Medical Affairs in bridging scientific validation, clinical practice and stakeholder engagement.

Key topics include:

• Scientific Validation and Evidence Generation: Learn how to ensure biomarker test reliability and reproducibility, which is critical for informed clinical decision-making and effective therapy adoption
• Market Access Strategies: Discover approaches to expand global reach, including onboarding Key Opinion Leaders (KOLs) for market insights, designing early access programs and enabling labs for biomarker testing
• Collaboration Between Stakeholders: Understanding the essential partnership between treating physicians and pathologists is crucial to ensure accurate result reporting and deliver the right therapy to the right patients
• Overcoming Diagnostic Challenges: Gain insights into navigating scenarios where a companion diagnostic (CDx) is unavailable, relying instead on lab-developed tests

This webinar will provide practical guidance on aligning cross-functional teams, driving adoption among healthcare professionals and ensuring the broadest patient access to biomarker-driven therapies as early as possible. By addressing both scientific and commercial considerations, attendees will leave equipped to enhance the success of their therapy launch on a global scale.

Register for this webinar to learn how to launch biomarker-driven therapy with global access and diagnostic success.

Keywords: Biomarkers, Commercial Launch Readiness, Commercialization/HEOR/Market Access, Companion Diagnostics, CRO, Drug Development, Early Access Programs, Precision Medicine, Product Launch, Therapeutic Areas